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Mechanisms of antibiotic resistance were examined in nalidixic acid-resistant Salmonella enterica serovar
Enteritidis field isolates displaying decreased susceptibility to ciprofloxacin and in in vitro-derived ciprofloxa-
cin-resistant mutants (104-cip and 5408-cip). All field isolates harbored a single gyrA mutation (D87Y).
Deletion of acrB and complementation with wild-type gyrA increased quinolone susceptibility. Selection for
ciprofloxacin resistance was associated with the development of an additional gyrA (S83F) mutation in 104-cip,
novel gyrB (E466D) and parE (V461G) mutations in 5408-cip, overexpression of acrB and decreased suscep-
tibility to nonquinolone antibiotics in both mutants, and decreased OmpF production and altered lipopoly-
saccharide in 104-cip. Complementation of mutated gyrA and gyrB with wild-type alleles restored susceptibility
to quinolones in 104-cip and significantly decreased the ciprofloxacin MIC in 5408-cip. Complementation of
parE had no effect on quinolone MICs. Deletion of acrB restored susceptibility to ciprofloxacin and other
antibiotics tested. Both soxS and marA were overexpressed in 104-cip, and ramA was overexpressed in 5408-cip.
Inactivation of each of these global regulators lowered ciprofloxacin MICs, decreased expression of acrB, and
restored susceptibility to other antibiotics. Mutations were found in soxR (R20H) and in soxS (E52K) in 104-cip
and in ramR (G25A) in 5408-cip. In conclusion, both efflux activity and a single gyrA mutation contribute to
nalidixic acid resistance and reduced ciprofloxacin sensitivity. Ciprofloxacin resistance and decreased suscep-
tibility to multiple antibiotics can result from different genetic events leading to development of target gene
mutations, increased efflux activity resulting from differential expression of global regulators associated with
mutations in their regulatory genes, and possible altered membrane permeability.
Salmonella enterica serovar Enteritidis is the most common
etiological agent of food-borne salmonellosis worldwide. Cip-
rofloxacin is the antibiotic of choice for the treatment of severe
Salmonella infections when therapeutic intervention is war-
ranted. To date, fluoroquinolone resistance (MIC of cipro-
floxacin, 4 g/ml) remains relatively uncommon in Salmo-
nella. However, the incidence of nalidixic acid resistance in
Salmonella isolates from humans and food animals has in-
creased, with these isolates showing decreased susceptibility to
fluoroquinolones (6, 27). Of paramount concern to public
health are reports of therapeutic failure of ciprofloxacin in
cases of invasive salmonellosis associated with isolates display-
ing reduced fluoroquinolone susceptibility (26, 30, 48).
Currently well-recognized mechanisms of quinolone resis-
tance in Salmonella include target gene mutations, increased
efflux pump activity, and plasmid-mediated protection of target
topoisomerases (13, 18). The contribution of changes in the
cell envelope, including porin loss or alterations of the lipo-
polysaccharide (LPS), to quinolone resistance is currently un-
clear (14, 29, 36). Nalidixic acid resistance and decreased sus-
ceptibility to ciprofloxacin have been largely associated with
single gyrA mutations at codon S83 or D87 (7, 18, 36). Double
mutations at both residues 83 and 87 have been found in
fluoroquinolone-resistant strains, often in association with mu-
tations in other topoisomerase genes (3, 4, 7). Overexpression
of the multidrug efflux pump AcrAB-TolC has been shown to
directly contribute to fluoroquinolone and multidrug resis-
tance (MDR) in Salmonella (3–5).
Much of our knowledge on the regulation of expression of
AcrAB comes from work carried out in Escherichia coli (34).
At a local level acrAB expression is modulated by the local
repressor AcrR, and at a global level it is modulated by MarA,
SoxS, and Rob, which belong to the AraC/XylS family of tran-
scriptional regulators (2). In addition to activating tolC and
acrAB genes, these transcriptional activators activate transcrip-
tion of micF, an antisense RNA that inhibits synthesis of the
OmpF outer membrane porin (34). Mutations within the local
repressor AcrR have also been shown to contribute to acrB
overexpression (33). The mar locus consists of two transcrip-
tion units, marC and marRAB, which are divergently tran-
scribed from a central putative operator-promoter region,
marO (10, 45). MarA regulates its own transcription as well as
regulating the expression of the mar regulon, whereas MarR
* Corresponding author. Mailing address: Centres for Food Safety
and Food-borne Zoonomics, UCD Veterinary Sciences Centre, Uni-
versity College Dublin, Belfield, Dublin 4, Ireland. Phone: (353-1) 716
6082. Fax: (353-1) 716 6091. E-mail: sfanning@ucd.ie.
 Published ahead of print on 22 December 2008.
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acts by repressing marRAB transcription. The functions of
MarB and MarC are unknown. marRAB transcription can also
be activated by the MarA homologs SoxS and Rob (2, 10, 45).
SoxS is the effector of the soxRS global superoxide response
regulon. SoxR is a constitutively expressed homodimeric tran-
scriptional regulator that contains redox-active iron-sulfur
clusters [2Fe-2S]. Oxidation of these clusters activates SoxR to
trigger transcription of the soxS gene (22, 50). Increased ex-
pression of these global regulators may be associated with
mutations in the regulatory genes of the operons (20, 21, 32) or
the selective binding of inducers (38, 39). As in E. coli, in-
creased expression of marA and soxS has been associated with
fluoroquinolone resistance and MDR in Salmonella (7, 12).
However, the contribution of these global regulators to over-
expression of acrAB in fluoroquinolone resistance and MDR
Salmonella phenotypes is still currently unclear. Furthermore,
little is known about rob and its contribution to antibiotic
resistance in Salmonella. More recently, RamA, which displays
close homology to MarA and is absent from E. coli, has been
implicated in MDR in Salmonella and other bacteria (1, 16, 19,
42). Overexpression of ramA has been associated with in-
creased expression of acrB in Salmonella and other Enterobac-
teriaceae (1, 19, 42).
In this study we examined the mechanisms of quinolone
resistance in nalidixic acid-resistant serovar Enteritidis field
isolates showing decreased susceptibility to ciprofloxacin. We
generated in vitro ciprofloxacin-resistant mutants from two of
these isolates in order to assess the contribution of target gene
mutations, altered membrane permeability, and active efflux to
the development of fluoroquinolone resistance and MDR. The
role of the global regulators marA, soxS, rob, and ramA in
upregulation of acrB and consequently in efflux-mediated
MDR was investigated. Local and global regulatory genes of
AcrAB-TolC were examined for the presence of mutations.
MATERIALS AND METHODS
Bacterial strains. Nine serovar Enteritidis strains of animal (54, 58, 51, and
104) and human (CUH48, CUH52, CUH60, 4931, and 5408) origin were used in
this study (Table 1). The serovar Enteritidis reference strain PT4 NCTC 13349
was also included. Ciprofloxacin-resistant mutants (104-cip and 5408-cip) were
selected from serovar Enteritidis strains 104 and 5408. Salmonella enterica sero-
var Typhimurium knockout strains L110 acrB::aph, L130 marA::aph, L133
ramA::aph, and L135 soxS::aph derived from SL1344 (12, 41) and donor E. coli
strains carrying the plasmids pBP513 gyrA, pBP548 gyrB, and pBP568 parE
were also used and kindly provided to L. Piddock by P. Heisig (15).
Selection of ciprofloxacin-resistant Salmonella mutants in vitro. Ciprofloxa-
cin-resistant mutants (104-cip and 5408-cip) were obtained by seven serial pas-
sages on tryptone soy agar (Oxoid, Hampshire, United Kingdom) containing
doubling concentrations of ciprofloxacin (0.25 to 16 g/ml; Sigma-Aldrich, Ire-
land). Colonies from the highest-concentration selecting plates were subcultured
five times on antibiotic-free medium before antibiotic sensitivities were deter-
mined. Mutants were stored on beads in cryopreservation fluid at 80°C (Tech-
nical Service Consultants Ltd., Lancashire, England).
Antimicrobial susceptibility testing. MICs of nalidixic acid, ciprofloxacin,
ampicillin, chloramphenicol, tetracycline, and sulfamethoxazole-trimethoprim
were determined by Etest on Mueller-Hinton agar following the manufacturer’s
instructions (AB-Biodisk, Solna, Sweden) and according to the Clinical and
Laboratory Standards Institute (CLSI) (9). E. coli ATCC 25922 and Pseudomo-
nas aeruginosa ATCC 27853 were used as quality control organisms. To assess
the contribution of efflux pump activity to intrinsic and acquired antibiotic re-
sistance, Etests were performed in the presence and absence of the efflux pump
TABLE 1. Phenotypic and genotypic characteristics of the serovar Enteritidis strains used in this study
Strain
MIC (g/ml) of druga,b: Amino acid substitution(s)c,d Fold change in expression of genee:
NAL CIP gyrA gyrB parE acrB soxS marA ramA rob
CUH48 6 (0.5) 0.016 (0.012) * * *
CUH52 3 (0.75) 0.016 (0.008) * * *
NCTC 13349 8 (0.38) 0.023 (0.008) * * *
54 256 (16) 0.19 (0.064) D87Y * *
58 256 (24) 0.125 (0.064) D87Y * *
51 256 (24) 0.19 (0.094) D87Y * *
51 acrB::aph 32 0.032 D87Y * *
CUH60 256 (32) 0.19 (0.094) D87Y * *
CUH60 acrB::aph 24 0.032 D87Y * *
4931 256 (16) 0.19 (0.064) D87Y * *
4931 acrB::aph 32 0.047 D87Y * *
104 256 (24) 0.19 (0.094) D87Y * *
104 gyrA 4 0.047 * * *
104 acrB::aph 32 0.032 D87Y * *
104-cip 256 (256) 32 (2) D87Y, S83F * * 6.1  1.5 26.1  4.0 8.9  0.6 1.2  0.2 4.6  0.2
104-cip gyrA 8 0.094 * * *
104-cip acrB::aph 256 0.38 D87Y, S83F * *
104-cip soxS::aph 256 1.5 D87Y, S83F * * 4.2  1.0 0.6  1.6
104-cip marA::aph 256 4 D87Y, S83F * * 1.4  0.3 1.4  0.2
5408 256 (24) 0.19 (0.094) D87Y * *
5408 gyrA 4 0.032 * * *
5408 acrB::aph 32 0.047 D87Y * *
5408-cip 256 (16) 32 (2) D87Y E466D V461G 5.4  1.6 3.4  0.5 1.3  0.2 33.7  4.0 2.3  1.0
5408-cip gyrA 256 1 * E466D V461G
5408-cip gyrB 256 3 D87Y * V461G
5408-cip parE 256 32 D87Y E466D *
5408-cip acrB::aph 256 0.5 D87Y E466D V461G
5408-cip ramA::aph 256 4 D87Y E466D V461G 1.6  0.1
a NAL, nalidixic acid; CIP, ciprofloxacin.
b Values in parentheses are the MICs determined in the presence of PAN at 80 g/ml.
c *, wild-type allele (no mutation).
d D, aspartic acid; Y, tyrosine; S, serine; F, phenylalanine; E, glutamic acid; V, valine; G, glycine.
e Gene expression data represent the means  standard deviations of three independent total RNA extractions. Changes in gene expression are relative to the
parental strain.
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inhibitor Phe-Arg--naphthylamide (PAN [80 g/ml]; Sigma-Aldrich). MICs of
PAN were 640 g/ml in all isolates.
PCR amplification and sequencing of QRDRs of quinolone target genes and
local and global regulators of AcrAB-TolC. Sequences of the primers used in the
PCR amplifications are given in Table 2. Genomic DNA was extracted from
overnight cultures in tryptone soy broth (Oxoid) at 37°C using a Wizard genomic
DNA purification kit (Promega, Madison, WI). PCR mixtures contained 100 ng
of template DNA, 100 pmol of each quinolone resistance-determining region
(QRDR) primer or 10 pmol of each regulator primer (MWG-Biotech AG,
Ebersberg, Germany), 200 M deoxynucleoside triphosphates (Promega), 1 U
Taq DNA polymerase (New England Biolabs, Ipswich, MA), and 1 PCR buffer
containing 2.5 mM MgCl2. After an initial denaturation step of 3 min at 94°C,
amplification was performed over 30 cycles, with each cycle consisting of 1 min
at 94°C, 1 min at appropriate annealing temperature (Table 2), and 1 min at
72°C, with a final extension step of 10 min at 72°C. PCR products were purified
with the Qiaquick spin PCR purification kit (Qiagen, West Sussex, United King-
dom) and sequenced commercially (Qiagen, Hilden, Germany).
Sequence analysis was carried out online using the programs BLAST (http:
//www.ncbi.nlm.nih.gov/BLAST/), CLUSTALW (http://www.ebi.ac.uk/Tools
/clustalw2/index.html), and Transeq (http://www.ebi.ac.uk/emboss/transeq/).
Accumulation of ciprofloxacin. Ciprofloxacin accumulation was measured by a
fluorometric method described by Mortimer and Piddock (31). Accumulation
experiments were performed with and without the addition of efflux pump
inhibitor PAN (final concentration, 80 g/ml) 6 min after the addition of
ciprofloxacin (final concentration, 10 g/ml). Fluorescence was measured with a
spectrofluorimeter (spectraMax Gemini; Molecular Devices, Sunnyvale, CA) at
excitation and emission wavelengths of 279 and 447 nm, respectively. The
amount of ciprofloxacin accumulated was calculated by comparison with a stan-
dard curve for ciprofloxacin (0.02 to 2.5 g/ml) in 0.1 M glycine hydrochloride
(pH 3.0). Results are expressed as nanograms of ciprofloxacin incorporated per
milligram (dry weight) of bacteria. All experiments were performed at least three
times to ensure reproducibility.
Expression analyses of efflux transporter gene acrB and global regulators.
Reverse transcription-PCR (RT-PCR) was used to assess gene expression of
acrB and global regulators soxS, marA, ramA, and rob. Overnight cultures were
diluted 1 in 100 in prewarmed LB broth and grown to mid-logarithmic phase
TABLE 2. Primers used in this study
Primer purpose and gene Primer sequence (5–3) Annealingtemp (°C)
Amplicon
size (bp) Reference or accession no.
QRDR
gyrA TGTCCGAGATGGCCTGAAGC 55 470 Modified from reference 6
CGTTAATCACTTCCGTCAG
gyrB GAAATGACCCGTCGTAAAGG 54 710 AE008878
TACAGTCTGCTCATCAGAAAG
parC ATGAGCGATATGGCAGAGCG 52 413 6
TGACCGAGTTCGCTTAACAG
parE GACCGAGCTGTTCCTTGTGG 52 493 6
GCGTAACTGCATCGGGTTCA
RT-PCR
16S rRNA GCGGCAGGCCTAACACAT 59/60 182 X80681
GCAAGAGGCCCGAACGTC
acrB TTTTGCAGGGCGCGGTCAGAATAC 59 184 This study
TGCGGTGCCCAGCTCAACGAT
soxS AAATCGGGCTACTCCAAGTG 59 217 9
CTACAGGCGGTGACGGTAAT
marA ATCCGCAGCCGTAAAATGAC 59 180 9
TGGTTCAGCGGCAGCATATA
rob CATTACGGCTGGGCGAGTTTACC 60 180 This study
CTGGCGGAATAGTTGGCGAATGAC
ramA CGTCATGCGGGGTATTCCAAGTG 60 107 This study
CGCGCCGCCAGTTTTAGC
Regulation
acrR CAGTGGTTCCGTTTTTAGTG 58 992 40
ACAGAATAGCGACACAGAAA
soxRS CGAACAGGGCGTCGTCGCTT 60 1,199 40
CTGGTTGCTAAAACGCGGCG
marORAB ACGGTGGTTAGCGGATTGGC 58 1,329 40
AGCGGCGGACTTGTCATAGC
ramA TTGCCGCTTCCAGTAATGCTTGTT 60 724 NC_003197
CTTTATCTGGCGGCGCTGGTTTTC
ramR CGTGTCGATAACCTGAGCGG 60 934 1
AAGGCAGTTCCAGCGCAAAG
Gene knockout verification
acrB GGATCACACCTTATTGCCAG 52 3,541a/2,107b 15
CGGCCTTATCAACAGTGAGC
marA GCGGACTTGTCATAGCCAGA 52 1,037a/1,818b 49
GCTGGATATCACCGCAACAC
soxS TACCGGCTATTCGAACTTGC 50 989a/1,912b 49
CTCGCTTAACGTATGTCCTT
ramA CCGCTTCCAGTAATGCTTGT 50 918a/1,755b 49
GAATCATTGATGACCGCTGC
a Without cassette.
b With cassette.
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(optical density at 600 nm [OD600], 0.6) with shaking at 37°C. A 1-ml aliquot of
each culture was pelleted by centrifugation at 15,339  g for 10 min, and RNA
was extracted immediately using a RiboPure-Yeast (Ambion, Texas) kit. Con-
taminating genomic DNA was eliminated by two DNase I treatments according
to the manufacturer’s instructions (Ambion), and its absence was confirmed by
including a reverse transcriptase-minus control on each RNA sample. Total
RNA concentration was estimated by OD260 using a Nanodrop ND-1000 spec-
trophotometer (Thermoscientific, Delaware). Real-time quantification of RNA
templates by real-time One-Step RT-PCR was performed in a Rotor Gene
3000 thermocycler (Corbett Research, Sydney, Australia) using a QuantiTect
SYBR Green RT-PCR kit (Qiagen, Hilden, Germany). The RT-PCR was
carried out in a 25-l reaction mixture containing 12.5 l 2 QuantiTect
SYBR Green RT-PCR Master Mix, 10 pmol of each primer (Table 2), 5 ng
of purified RNA template, and 0.25 l of QuantiTect RT mix. Initial reverse
transcription at 50°C for 30 min was followed by a denaturation step of 15 min
at 95°C. Amplification was then performed over 35 cycles, with each cycle
consisting of 15 s at 94°C, 30 s at appropriate annealing temperature (Table
2), and 30 s at 72°C, with a final melting step. Within bacterial cells, the level
of 16S rRNA was assumed to be transcribed at a constant rate throughout the
growth conditions in this study. Relative gene expression was calculated using
the threshold cycle method (24).
Phenotype microarray. Ciprofloxacin-sensitive parents and ciprofloxacin-resis-
tant mutants were examined for cellular phenotypes using Omnilog phenotype
microarrays (PM11-20) (Biolog, Inc., Hayward, CA). Briefly, bacteria were
grown on blood agar overnight at 37°C. Colonies were picked with a sterile
cotton swab and suspended in 10 ml IF-0a (Biolog), and the cell density was
adjusted to an OD600 of 0.035 on a spectrophotometer (Biomate 5; Thermo-
spectronic, Cambridge, United Kingdom). A 750-l aliquot of this cell suspen-
sion was added to 150 ml IF-10 (Biolog). Microtiter plates were inoculated with
100 l of cell suspension per well, incubated at 37°C for 48 h in the Omnilog, and
monitored continuously for color changes in the wells. Kinetic data were ana-
lyzed with Omnilog PM software.
Complementation. The relevance of target gene mutations in 104-cip and
5408-cip was evaluated by complementation assays. Plasmids containing the
wild-type alleles were introduced into the mutant cells by electrotransformation,
and transformants were selected on LB agar supplemented with 50 g/ml kana-
mycin and incubated at 37°C overnight. Quinolone MICs of transformants were
compared to those of parent and mutant strains using Etest strips.
P22 transduction. Gene deletions (acrB, marA, soxS, and ramA) from SL1344
mutants were transduced into bacterial isolates by using P22 phage according to
standard procedures. The resulting deletional mutants were selected on LB agar
containing 50 g/ml kanamycin, and insertion of the kanamycin resistance gene
into mutants was confirmed by PCR using primers listed in Table 2.
Analysis of LPS: cell lysis and proteinase K digestion. LPS was isolated by
proteinase K treatment of bacterial cells as described by Hitchcock and Brown
(17). LPS preparations were subjected to sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis with a 4% (wt/vol) stacking gel and a 15% (wt/vol)
separating gel. LPS from Salmonella enterica serotype Minnesota (Sigma-Al-
drich) was used as a smooth LPS control. A full-range rainbow molecular weight
marker was used as the size standard (Amersham, England). Following electro-
phoresis, the LPS was visualized by silver staining as previously described by Tsai
and Frasch (47).
SDS-polyacrylamide gel electrophoresis analyses and immunocharacteriza-
tion. Exponential-phase bacteria in LB broth were pelleted and solubilized in
boiling buffer at 96°C as previously described (25). Equal amounts of total cell
protein (OD600 	 0.01) were loaded onto an SDS-polyacrylamide gel (10%
polyacrylamide, 0.1% SDS). Gels were stained with Coomassie brilliant blue
R-250 (0.25% [wt/vol]). For Western blots, proteins were electrotransferred onto
nitrocellulose membranes in transfer buffer (25). An initial saturating step was
performed overnight at 4°C with Tris-buffered sodium (TBS; 50 mM Tris-HCl
[pH 8.0], 150 mM NaCl) containing skim milk powder (10%). The nitrocellulose
sheets were then incubated in TBS containing skim milk powder (10%) and
Triton X-100 (0.2%) for 2 h at room temperature in the presence of polyclonal
antibodies (1:2,000 dilution) directed against denatured OmpF porin or with F4
polyclonal antibody directed against the L3 internal loop of E. coli porins (11).
These antibodies directed against denatured OmpF and the L3 internal porin
loop recognized the denatured enterobacterial porins including Salmonella F and
D porins (44). The detection of antigen-antibody complexes was performed with
alkaline phosphatase-conjugated AffinitiPure goat anti-rabbit immunoglobulin G
antibodies as previously reported (25).
RESULTS
Antimicrobial susceptibility. Two field isolates (CUH48 and
CUH52) and the reference strain (NCTC 13349) were fully
susceptible to nalidixic acid (MICs, 8 g/ml) and ciprofloxa-
cin (MICs, 0.023 g/ml). Seven strains showing high-level
nalidixic acid resistance (MIC, 256 g/ml) displayed de-
creased susceptibility to ciprofloxacin (MICs between 0.125
and 0.19 g/ml). The ciprofloxacin-selected mutants, 104-cip
and 5408-cip, displayed high-level quinolone resistance (nali-
dixic acid MICs,256 g/ml; ciprofloxacin MICs,32 g/ml).
Additionally, 104-cip showed decreased susceptibility to tetra-
cycline, ampicillin, and chloramphenicol and 5408-cip showed
decreased susceptibility to sulfamethoxazole-trimethoprim,
ampicillin, and chloramphenicol (Table 3). Phenotype mi-
croarray analysis showed that 104-cip tested resistant to 36
antimicrobials including beta-lactams, narrow- and expanded-
spectrum cephalosporins, chloramphenicol, tetracycline, fun-
gicides, and biocides. Similarly, 5408-cip tested resistant to 23
antimicrobials, including beta-lactams, narrow- and expanded-
spectrum cephalosporins, chloramphenicol, folate synthesis in-
hibitors, macrolides, aminoglycosides, and chelators (data not
shown).
Contribution of target gene mutations to quinolone resis-
tance. Fully quinolone-susceptible strains had no mutations in
the target genes (Table 1). A single gyrA mutation (D87Y) was
present in all strains showing high-level nalidixic acid resis-
tance. Complementation of gyrA in both 104 and 5408 reduced
nalidixic acid MICs to 4 g/ml in both isolates and decreased
ciprofloxacin MICs to 0.047 g/ml and 0.032 g/ml, respec-
tively. In 104-cip an additional mutation in gyrA (S83F) was
associated with the development of high-level ciprofloxacin
resistance. In 5408-cip novel mutations were detected in gyrB
(E466D) and parE (V461G) (Table 1). Complementation of
gyrA in 104-cip (S83F, D87Y) restored susceptibility to nali-
dixic acid (MIC, 8 g/ml) and ciprofloxacin (MIC, 0.094 g/
ml). Complementation of gyrA and gyrB in 5408-cip reduced
ciprofloxacin MICs to 1 and 3 g/ml, respectively. Comple-
mentation of parE in 5408-cip had no effect on quinolone
MICs (Table 1).
TABLE 3. Antimicrobial susceptibilities of wild-type serovar
Enteritidis strains, their isogenic ciprofloxacin-resistant
mutants, and deletional mutants
Strain
MIC (g/ml) of druga:
TC TS AM CL
104 1 (0.19) 0.094 (0.023) 1 (0.75) 2 (0.75)
104-cip 12 (3) 0.19 (0.023) 16 (1) 96 (1)
104-cip acrB::aph 0.25 0.008 0.125 0.75
104-cip marA::aph 1.5 0.064 1.5 3
104-cip soxS::aph 0.75 0.016 0.5 1.5
5408 1 (0.19) 0.064 (0.023) 1 (1) 3 (0.5)
5408-cip 1.5 (0.094) 0.25 (0.032) 4 (2) 16 (0.38)
5408-cip acrB::aph 0.094 0.023 0.094 0.5
5408-cip ramA::aph 1 0.064 1 3
a AM, ampicillin; CL, chloramphenicol; TC, tetracycline; TS, trimethoprim-
sulfamethoxazole. Values in parentheses are disk diffusion results in the presence
of efflux pump inhibitor PAN at 80 g/ml. Values represent means of three
separate determinations.
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Contribution of efflux pump activity to antibiotic resistance.
The contribution of efflux pump activity to antibiotic resistance
was assessed by use of the efflux pump inhibitor PAN. PAN
decreased the MIC of nalidixic acid and ciprofloxacin in all
wild-type strains (Table 1). It decreased the MIC of ciprofloxa-
cin in 104-cip to 2 g/ml but had no effect on the MIC of
nalidixic acid. The MICs of both nalidixic acid and ciprofloxa-
cin in 5408-cip were reduced to 16 g/ml and 2 g/ml, respec-
tively, in the presence of PAN (Table 1). The susceptibility of
ciprofloxacin-resistant mutants to other antibiotics was also
restored in the presence of PAN (Table 3). Both mutants
accumulated less ciprofloxacin than did their isogenic parents
(Fig. 1). Addition of PAN increased ciprofloxacin accumula-
tion in both mutants and parents, the two eventually reaching
identical steady-state levels of cell-associated ciprofloxacin.
Contribution of AcrAB-TolC to antibiotic resistance. 104-cip
and 5408-cip showed increased expression of acrB (6.1-  1.5-
and 5.4-  1.6-fold increases, respectively). Deletion of acrB
decreased the MIC of ciprofloxacin from 32 to 0.38 g/ml in
104-cip and from 32 to 0.5 g/ml in 5408-cip and had no
effect on the MICs of nalidixic acid (Table 1). Susceptibility to
other classes of antibiotics was also restored in both deletional
mutants (Table 3). Deletion of acrB also decreased the MICs
of ciprofloxacin and nalidixic acid in isolates (51, CUH60,
4931, 104, and 5408) showing nalidixic acid resistance and
decreased susceptibility to ciprofloxacin (Table 1).
Contribution of global regulators to antibiotic resistance. In
104-cip there was a 26.1- 4.0-fold increase in soxS expression
and an 8.9- 0.6-fold increase in marA expression. Deletion of
soxS in 104-cip decreased the expression of acrB by 4.2- 
1.0-fold and the expression of marA by 0.6-  1.6-fold and
decreased the ciprofloxacin MIC to 1.5 g/ml (Table 1). De-
letion of marA in 104-cip decreased the expression of acrB by
1.4-  0.3-fold and the expression of soxS by 1.4-  0.2-fold
and decreased the ciprofloxacin MIC to 4 g/ml. Both marA
and soxS deletional mutants remained nalidixic acid resistant
(256 g/ml) but lost their MDR phenotype (Table 3). In
5408-cip there was significantly increased expression of ramA
(33.7-  4.0-fold). Deletion of ramA in 5408-cip reduced acrB
expression by 1.6-  0.1-fold and decreased the MIC of cip-
rofloxacin to 4 g/ml. It had no effect on the MIC of nalidixic
acid (256 g/ml) (Table 1). The ramA deletional mutant
became susceptible to other classes of antibiotics (Table 3).
Expression of rob was found to be decreased in both mutants
(Table 1).
Genetic analysis of local and global regulators. Mutations
were found in soxR (R20H) and in soxS (E52K) in 104-cip. The
soxR mutation mapped to the helix-turn-helix region of the
SoxR protein. A mutation was also found in ramR (G25A) in
5408-cip, which is found upstream of ramA. No mutations were
found in the local regulator acrR or the global regulators
marORAB and ramA.
Porin expression and LPS profiles. Immunodetection of
OmpF with polyclonal antibodies directed against the dena-
tured OmpF porin and with an F4 polyclonal antibody directed
against the L3 internal loop of E. coli porins revealed a de-
crease in the production of OmpF in 104-cip (Fig. 2). All
isolates displayed a smooth LPS phenotype. The LPS profile of
104-cip showed significant loss of short and intermediate O-
chain LPSs compared to its isogenic parent (data not shown).
No changes were observed in the LPS or OmpF profile of
5408-cip.
FIG. 1. Accumulation of ciprofloxacin in in vitro-selected cipro-
floxacin-resistant serovar Enteritidis isolates (104-cip and 5408-cip)
and their isogenic parent strains (104 and 5408) in the presence and
absence of PAN (80 g/ml). Ciprofloxacin (10 g/ml) was added to
each bacterial suspension at time zero. PAN was added at 6 min as
indicated by the arrow. Each value represents the mean  standard
error of the mean of three or four separate experiments.
FIG. 2. The detection of porins was carried out using the polyclonal antibodies directed against denatured OmpF porin (A) or the F4 polyclonal
antibody directed against the L3 internal loop of E. coli porins (B). Lanes 1, 104; lanes 2, 104-cip; lanes 3, 5408; lanes 4, 5408-cip, lanes 5, NCTC
13349. Arrows indicate the migration of F and D porins, respectively.
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DISCUSSION
In this study, we confirmed that both AcrAB-TolC efflux
pump activity and a D87 mutation in gyrA contribute to quin-
olone resistance in serovar Enteritidis field isolates displaying
high-level nalidixic acid resistance and decreased susceptibility
to fluoroquinolones (7). Ciprofloxacin-resistant and MDR mu-
tants were readily selected in vitro from two of these field
isolates, highlighting the ease with which resistance to fluoro-
quinolones and other clinically important antibiotics could po-
tentially emerge during prolonged fluoroquinolone therapy in
infected patients. Selection for high-level ciprofloxacin resis-
tance was associated with the development of an additional
gyrA mutation in 104-cip and hitherto-undocumented muta-
tions in gyrB and parE in 5408-cip, overexpression of acrB and
the development of an MDR phenotype in both isolates, and a
decrease in OmpF expression and altered LPS in 104-cip.
Double mutations in gyrA have been widely reported in
ciprofloxacin-resistant Salmonella isolates, whereas mutations
in gyrB and parE in Salmonella are rarely detected (18). By
complementation, we defined a significant role for the double
gyrA mutations (D87Y and S83F) in quinolone resistance in
104-cip and for the single gyrA (D87Y) and the novel gyrB
(E466D) mutation in ciprofloxacin resistance in 5408-cip. Al-
though complementation with wild-type parE was without ef-
fect, the possibility that parE mutations may indirectly contrib-
ute to high-level fluoroquinolone resistance by increasing the
level of resistance in isolates already harboring target gene
mutations cannot be excluded (23).
Consistent with increased expression of an RND multidrug
efflux pump, both mutants displayed an MDR phenotype. The
increase in acrB expression was reflected in the decrease ob-
served in ciprofloxacin accumulation, which increased follow-
ing addition of PAN. Inactivation of acrB restored suscepti-
bility to ciprofloxacin and other nonquinolone antibiotics
tested in accordance with previous reports that overexpression
of AcrAB-TolC contributes to fluoroquinolone resistance and
MDR in Salmonella (3–5). Similar effects were observed with
PAN, highlighting its utility as a pharmacological tool to
screen for efflux-mediated antibiotic resistance in Salmonella.
Interestingly, we observed a reproducible discrepancy between
the effects of PAN and deletion of acrB on nalidixic acid
resistance in 5408-cip. The possibility of the contribution of an
unidentified efflux pump, sensitive to PAN, to nalidixic acid
resistance in this isolate cannot be excluded.
The increased expression of acrB was associated with differ-
ential expression of global regulators, with 104-cip showing
increased expression of both soxS and marA and 5408-cip
showing increased expression of ramA. By deleting each of
these regulators, we provided direct evidence for their involve-
ment in fluoroquinolone resistance and MDR in serovar En-
teritidis through acrB activation. To the best of our knowledge,
this is the first report to document a direct contribution of
marA and soxS to AcrAB-mediated MDR in Salmonella. Com-
pared to the marA deletional mutant, the soxS deletional mu-
tant showed greater downregulation of acrB and displayed
lower MICs of ciprofloxacin and other antibiotics tested. These
data suggest that soxS plays a greater role than marA in MDR
in 104-cip. Expression of marA decreased following deletion of
soxS and vice versa, highlighting the cross-regulation that exists
between these transcriptional factors (12, 43). Recently, ramA
has been reported to contribute to fluoroquinolone resistance
and MDR in serovar Typhimurium through activation of acrB
(1). Similarly our data clearly define a regulatory role for ramA
in AcrAB-mediated MDR in serovar Enteritidis and further-
more show that ramA activates the MDR cascade indepen-
dently of marA. As overexpression of rob has been shown to
confer MDR in E. coli through activation of acrB (46), it is
reasonable to assume a lack of involvement of this regulator in
the development of MDR in this study. The decreased expres-
sion of rob in 104-cip is likely due to downregulation by soxS
and marA (28, 43). The nature and extent of the cross talk
between ramA and other global regulators are currently un-
known. However, based on our data it would be interesting to
speculate that it may downregulate both soxS and rob.
Increased expression of soxS and marA in E. coli has been
attributed to mutations in the soxR gene that render soxR
active independent of oxidative stress or mutations in marR
that alleviate its repression of marA (21, 32, 49). To date, there
is only one report documenting the contribution of a mutation
in soxR to increased soxS expression and MDR in Salmonella
(20). We identified mutations in both soxR and soxS in 104-cip.
The same soxR mutation has been linked to increased soxS
expression and multiple antibiotic resistance in E. coli (21).
Mutations in soxS have been reported in E. coli isolates over-
expressing soxS, but their significance was not determined (49).
Similar to other studies of Salmonella (7, 12), we found no
mutations in the marR or marO region that could explain the
increased expression of marA. Therefore, it most likely re-
sulted from feed-forward activation by SoxS. Sequence analysis
also revealed a hitherto-unreported mutation within the re-
cently defined local repressor ramR (G25A) of ramA in 5408-
cip. Mutations in ramR have been reported to play a role in
upregulation of ramA and AcrAB and consequently the efflux-
mediated MDR phenotype in serovar Typhimurium (1). The
significance of these mutations in soxR, soxS, and ramR is
currently being investigated.
OmpF expression was decreased in 104-cip, consistent with
the role of marRAB and soxRS in the control of its expression
(37, 40). This mutant also displayed alterations in the LPS
ladder. In contrast to the findings in Enterobacter aerogenes and
E. coli (8), ramA-mediated MDR in 5408-cip was not associ-
ated with downregulation of porins. Few studies have investi-
gated OmpF expression in fluoroquinolone-resistant Salmo-
nella, and its contribution to resistance is unclear (14, 29, 35).
Only one study to date has documented alterations in the LPS
profile in fluoroquinolone-resistant Salmonella, and the au-
thors suggested that the increase in the proportion of long
O-chain LPSs observed could result in a lower level of antibi-
otic accessibility to the porins (14). Further studies are war-
ranted to evaluate the exact contribution of altered porin
expression and LPS to antibiotic resistance in 104-cip. None-
theless, based on our data showing that both 104-cip and its
isogenic parent accumulated the same amount of ciprofloxacin
at steady state following the addition of PAN, it would appear
that the decreased accumulation of ciprofloxacin observed in
104-cip was mainly due to enhanced efflux activity rather than
decreased influx resulting from altered membrane permeabil-
ity. Furthermore, the hypersusceptibility to ampicillin, tetracy-
cline, and chloramphenicol (which also enter through the porin
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pathway) observed following deletion of acrB also suggests that
active efflux is the main mechanism associated with MDR in
this isolate.
Finally, this study revealed that different mechanisms were
involved in the development of MDR following ciprofloxacin
exposure, as the two mutants displayed different phenotypes of
resistance to nonquinolone antibiotics. It is possible that these
differences may be due to pleiotropic effects associated with
the different expression profiles of global regulators observed
in these isolates.
In summary, this study highlights that a high-level cipro-
floxacin resistance and MDR phenotype in serovar Enteritidis
can result from different genetic events associated with multi-
ple resistance mechanisms. It provides direct evidence that
quinolone resistance and MDR in serovar Enteritidis result
from interplay between target gene mutations and increased
AcrAB-TolC efflux activity and defines a role for a novel gyrB
mutation in ciprofloxacin resistance. Increased AcrAB-TolC
efflux activity in fluoroquinolone-resistant and MDR isolates
can be due to differential expression of the global regulators
soxS, marA, and ramA associated with mutations in their reg-
ulatory genes.
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